

Parameter		All 258 cases N (range)
Age		57.21 (30-86)
nulligravida		55
nullipara		66
menopause		181
FIGO clinical stage	I	213
	II	11
	III	22
	IV	12
Tumor grade	1	157
	2	76
	3	25
malignant ascites	Positive	68
	Negative	190
ER	Positive	190
	Negative	68
PR	Positive	205
	Negative	53

Parameters		All 241 cases	Stage I		p-value	Advanced stage (Stage III and IV)		p-value
			201 cases			31 cases		
			SOX2 positive (n=33)	SOX2 negative (n=168)		SOX2 positive (n=8)	SOX2 negative (n=23)	
Age		57.65 (30-86)	64.64 (41-86)	56.73 (30-85)	<0.001	53.5 (33-75)	57.04 (34-81)	0.548
nulligravida		50	8	28	0.299	3	9	0.784
nullipara		59	8	35	0.662	4	10	0.926
menopause		173	29	118	0.06	4	16	0.571
FIGO clinical stage	I	201	33	168		-	-	
	II	9	-	-		-	-	
	III	19	-	-		2	17	
	IV	12	-	-		6	6	
Tumor grade	1	143	13	114	<0.001	0	10	<0.01
	2	73	10	48		2	10	
	3	25	10	6		6	3	
malignant ascites	Positive	61	8	35		6	12	
	Negative	180	25	133	0.662	2	11	0.477
ER	Positive	175	21	127		3	18	
	Negative	66	12	41	0.154	5	5	0.092
PR	Positive	190	22	137		4	19	
	Negative	51	11	31	0.055	4	4	0.178

A

parameters	N (%)	OS		PFS		
		HR (95%CI)	p-value	HR (95%CI)	p-value	
Tumor grade	1	10 (32.3)				
	2,3	21 (67.7)	2.302 (0.5774-7.041)	0.2717	2.517 (0.7866-6.055)	0.1339
malignant ascites	Positive	18 (58.1)	1.922 (0.5501-6.046)	0.3258	2.212 (0.7591-5.559)	0.1564
	Negative	13 (41.9)				
ER	Positive	21 (67.7)	3.001 (0.9717-13.47)	0.0552	2.187 (0.8165-7.723)	0.1082
	Negative	10 (32.3)				
PR	Positive	23 (74.2)	3.012 (0.9722-17.31)	0.0547	4.084 (2.173-32.93)	0.0021
	Negative	8 (25.8)				
SOX2 expression	Positive	8 (25.8)	3.398 (1.166-23.19)	0.0307	3.949 (2.036-29.97)	0.0027
	Negative	23 (74.2)				

B

parameters	N (%)	PFS	
		HR (95%CI)	p-value
PR	Positive	23 (74.2)	
	Negative	8 (25.8)	3.593 0.0264
SOX2 expression	Positive	8 (74.2)	
	Negative	23 (25.8)	3.491 0.0289

A

parameters	N (%)	OS		PFS	
		HR (95%CI)	p-value	HR (95%CI)	p-value
Tumor grade	1	127 (63.2)			
	2, 3	74 (36.8)	(-)	4.933 (1.514-18.03)	0.0089
malignant ascites	Positive	43 (21.4)	7.477 (0.9640-247.1)	3.121 (1.017-18.45)	0.0474
	Negative	158 (78.6)			
ER	Positive	148 (73.6)	5.557 (0.6069-102.6)	1.623 (0.4445-6.570)	0.4354
	Negative	53 (26.4)			
PR	Positive	159 (79.1)	7.552 (0.9813-255.6)	2.274 (0.6308-12.06)	0.1777
	Negative	42 (20.9)			
SOX2 expression	Positive	33 (16.4)	0 (0.01439-6.320)	4.67 (2.048-55.75)	0.0049
	Negative	168 (83.6)			

B

parameters	N (%)	PFS	
		HR (95%CI)	p-value
Tumor grade	1	127 (63.2)	
	2, 3	74 (36.8)	3.325 (0.840-16.315)
malignant ascites	Positive	43 (21.4)	2.736 (0.729-10.052)
	Negative	158 (78.6)	
ER	Positive	148 (73.6)	1.251 (0.200-9.694)
	Negative	53 (26.4)	
PR	Positive	159 (79.1)	
	Negative	42 (20.9)	1.664 (0.229-10.825)
Sox2 expression	Positive	33 (16.4)	3.097 (0.843-10.977)
	Negative	168 (83.6)	

Antigen	Supplier	Catalog number	Applications
SOX2	Cell Signaling Techonologies	3579	WB, IHC, ICC, ChIP
NANOG	Abcam	ab21624	WB
OCT-3/4	Abcam	ab1957	WB
p21 ^{Waf1/Cip1}	Cell Signaling Techonologies	2947	WB, IHC
p27 ^{Kip1}	Cell Signaling Techonologies	3686	WB
cyclinD1	Cell Signaling Techonologies	2926	WB
GAPDH	Millipore	MAB374	WB
Palloidin	Cell Signaling Techonologies	8953	ICC
p53	Dako	M7001	IHC
Ki-67	Dako	M7240	IHC